JP2024534575A5 - - Google Patents
Info
- Publication number
- JP2024534575A5 JP2024534575A5 JP2024518410A JP2024518410A JP2024534575A5 JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5 JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024518410 A JP2024518410 A JP 2024518410A JP 2024534575 A5 JP2024534575 A5 JP 2024534575A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025171713A JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247236P | 2021-09-22 | 2021-09-22 | |
| US63/247,236 | 2021-09-22 | ||
| US202163255333P | 2021-10-13 | 2021-10-13 | |
| US63/255,333 | 2021-10-13 | ||
| US202263389679P | 2022-07-15 | 2022-07-15 | |
| US63/389,679 | 2022-07-15 | ||
| PCT/US2022/044453 WO2023049299A2 (en) | 2021-09-22 | 2022-09-22 | Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Division JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534575A JP2024534575A (ja) | 2024-09-20 |
| JPWO2023049299A5 JPWO2023049299A5 (https=) | 2025-10-21 |
| JP2024534575A5 true JP2024534575A5 (https=) | 2025-10-21 |
Family
ID=85721146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518410A Pending JP2024534575A (ja) | 2021-09-22 | 2022-09-22 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171713A Pending JP2026012737A (ja) | 2021-09-22 | 2025-10-10 | Ｐｃｓｋ９又はａｎｇｐｔｌ３の遺伝子編集、並びに疾患の治療のためにそれらを使用する組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390520A1 (https=) |
| EP (1) | EP4405470A2 (https=) |
| JP (2) | JP2024534575A (https=) |
| KR (2) | KR20250160515A (https=) |
| AU (1) | AU2022349449A1 (https=) |
| CA (1) | CA3232742A1 (https=) |
| GB (3) | GB2700667A (https=) |
| IL (1) | IL311607A (https=) |
| MX (1) | MX2024003570A (https=) |
| WO (1) | WO2023049299A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4545544A3 (en) * | 2015-06-29 | 2025-10-08 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| CN121555430A (zh) | 2018-05-11 | 2026-02-24 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2025137465A1 (en) * | 2023-12-21 | 2025-06-26 | Beam Therapeutics Inc. | Base editors with modified editing windows |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| EP3250691B9 (en) * | 2015-01-28 | 2023-08-02 | Caribou Biosciences, Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
| JP7109784B2 (ja) * | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
-
2022
- 2022-09-22 AU AU2022349449A patent/AU2022349449A1/en active Pending
- 2022-09-22 GB GB2509407.9A patent/GB2700667A/en active Pending
- 2022-09-22 JP JP2024518410A patent/JP2024534575A/ja active Pending
- 2022-09-22 MX MX2024003570A patent/MX2024003570A/es unknown
- 2022-09-22 KR KR1020257035760A patent/KR20250160515A/ko active Pending
- 2022-09-22 KR KR1020247013385A patent/KR20240099200A/ko active Pending
- 2022-09-22 GB GBGB2509406.1A patent/GB202509406D0/en active Pending
- 2022-09-22 CA CA3232742A patent/CA3232742A1/en active Pending
- 2022-09-22 IL IL311607A patent/IL311607A/en unknown
- 2022-09-22 WO PCT/US2022/044453 patent/WO2023049299A2/en not_active Ceased
- 2022-09-22 EP EP22873600.5A patent/EP4405470A2/en active Pending
- 2022-09-22 GB GB2405381.1A patent/GB2628238A/en active Pending
-
2024
- 2024-03-21 US US18/611,988 patent/US20240390520A1/en active Pending
-
2025
- 2025-10-10 JP JP2025171713A patent/JP2026012737A/ja active Pending